X

CTS History

01Dec

Babesia

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

CTS Business Continuity Plan

CTS Business Continuity Plan

As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...

Read More >

Operational Excellence

CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...

Read More >
Zika Testing

Zika Testing

In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...

Read More >
Pooled Babesia

Pooled Babesia

Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...

Read More >
Dengue Testing

Dengue Testing

CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.

Read More >
Disaster Reliability via Merged Information Systems

Disaster Reliability via Merged Information Systems

In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...

Read More >